HIV AIDS

Oral lesions, often the harbingers of early HIV infection, rank among the most common complaints for which HIV-positive patients seek primary care. Here we offer visual presentations of these and other lesions associated with HIV.

Antiretroviral therapy has greatly reduced the incidence of non-Hodgkin lymphoma. But, a new study finds the risk is still high even at low levels of HIV infection.

As the number of patients with HIV who are treated effectively continues to rise, so too will the number of these patients seen for routine primary care. Here, 6 studies to help PCPs offer optimal treatment for this population.

A toddler from Nigeria, whose parents remained there ill with AIDS, presented with a fever and a widespread itchy eruption. Tests for HIV infection were positive. Which systemic etiologies can be ruled out when such an eruption presents?

Asymptomatic neurocognitive impairment is common among HIV-infected patients. Can it be used to predict future cognitive decline? New research answers the question.

A recent study examined the improvement in life expectancy associated with CD4+ cell count response and viral suppression status in patients on combination antiretroviral therapy.

With the advent of powerful antiretroviral therapies, rates of pulmonary malignancy have declined in HIV-infected patients. But, say results of a new study, we can’t take malignant causes out of the differential yet.

Tinnitus and hearing loss in HIV infection; allodynia in which pain conditions; aphthous ulcers. . . 5 questions here to challenge your diagnostic and clinical IQ.

The increased risk was independent of potential confounders such as fracture history, alcohol abuse, or use of drugs such as corticosteroids.

A recent trial provides encouraging evidence that vaccination against other infectious diseases may provide protection for persons infected with HIV.

Adherence with antiretroviral therapy among HIV-infected women was as low as 50% at the time the first fixed-combination, single-dose tablet was introduced.

A new study investigates the impact of epidemiologic factors on time trends for AIDS-defining and non–AIDS-defining cancers.

The downward trend in incidence parallels increased life expectancy among infected patients stabilized with HAART. However, a new study finds that not all populations are equally affected.

A recent study uses results of advanced coronary vessel imaging to compare the presence and extent of subclinical atherosclerosis in HIV-infected and non-infected men.

Prevention counseling has been shown to reduce sexual risk-taking among HIV-infected patients. A new study shows, however, that very few of the highest-risk patients receive intervention.

Treatment for HIV infection initiated within 3 months of diagnosis can shorten time to viral suppression, a new study finds.

These presentations provided a wealth of data suggesting that very early treatment of HIV may help control viremia and achieve remission over time in pediatric patients.

Here: 4 subgroups of HIV patients whose cardiovascular health might benefit from your targeted intervention.

Useful details here about HIV and age-related issues, sexual dysfunction, heart disease, and end-organ damage.

These suggestions will enhance your enjoyment of long meetings and will have your colleagues remarking on what a jolly, friendly person you really are. Ignore the advice at your own peril.

The good: this premier HIV conference offers a banquet of exceptional material. The bad: the expense and the grind of covering a meeting this rich-and lengthy.

Two studies demonstrate that raltegravir is an extremely well-tolerated and potent component of a combination antiretroviral regimen.

Replication of HIV within the CNS continues to be a hot topic, because it represents a viral reservoir that can complicate treatment, as well as control and prevention efforts.

“Super-spreaders” continue to play a major role in various epidemics, including tuberculosis and HIV infection.

Preliminary study results confirm that patient education and targeting those in higher-risk populations or who engage in high-risk behaviors continue to be important in preventing HIV transmission. Four specific recommendations here.

It is quite likely that we have entered a new era of treatment for individuals either mono-infected with HCV or co-infected with HCV/HIV. Details here.

The START trial is likely to provide a definitive answer to one of the most important clinical questions in HIV management: when is the optimal time to start antiretroviral therapy.

Better understanding of this complex condition can lead to better patient care and prevention. This week’s photo quiz offers several presentations to test your knowledge.

Stark defunding for AIDS research may lead to increased pharmaceutical influence, less population diversity in research, and dwindling new HIV-specific advances.

Hepatocellular carcinoma can develop in HIV/HCV-coinfected patients with a previous sustained virological response with interferon-based therapy. Continued surveillance for HCC with ultrasound examinations in patients with cirrhosis who respond to anti-HCV therapy is recommended.